Scullard G H, Alberti A, Wansbrough-Jones M H, Howard C R, Eddleston A L, Zuckerman A J, Cantell K, Williams R
J Clin Lab Immunol. 1979 Feb;1(4):277-82.
Eight patients with chronic hepatitis B infection (seven with chronic active hepatitis and one with chronic persistent hepatitis) were treated with daily intramuscular injections of human leucocyte interferon for periods of 5 to 8 weeks and in one case for 5 months. In one patient there was a marked fall in virus-associated DNA polymerase activity and in the number of DNA containing viral particles during each of two courses of interferon. Hepatitis Be antigen (HBeAg) also disappeared, the aspartate transaminase levels fell and liver histology improved. In the four other patients with detectable DNA polymerase activity there was an early fall but this was transient and in one of these patients there was a continuing rise in activity despite treatment. One other patient became HBeAg negative but hepatitis B surface antigen (HBsAg) titres were mostly unaffected by treatment. A marked decrease in T-lymphocyte mediated cytotoxicity towards HBsAg coated target cells was demonstrated and raises the possibility that an immunosuppressant action of interferon may offsets its direct anti-viral action but may also account for the improvement in liver function which occurred in some patients.
8例慢性乙型肝炎感染患者(7例慢性活动性肝炎,1例慢性持续性肝炎)接受了为期5至8周、1例为5个月的每日肌肉注射人白细胞干扰素治疗。在1例患者中,在两个疗程的干扰素治疗期间,病毒相关DNA聚合酶活性和含病毒颗粒的DNA数量均显著下降。乙肝e抗原(HBeAg)也消失了,天冬氨酸转氨酶水平下降,肝脏组织学改善。在其他4例可检测到DNA聚合酶活性的患者中,活性早期下降,但为短暂性,其中1例患者尽管接受治疗但活性仍持续上升。另1例患者HBeAg转为阴性,但乙肝表面抗原(HBsAg)滴度大多不受治疗影响。对包被HBsAg的靶细胞的T淋巴细胞介导的细胞毒性显著降低,这提示干扰素的免疫抑制作用可能抵消其直接抗病毒作用,但也可能解释了部分患者肝功能的改善。